Boris A Ratsch
Overview
Explore the profile of Boris A Ratsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
238
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scheid C, Blau I, Sellner L, Ratsch B, Basic E
Eur J Haematol
. 2020 Sep;
106(2):148-157.
PMID: 32989806
Objectives: Emerging treatments for relapsed or refractory multiple myeloma (rrMM) have led to increasing options for many patients. This study aimed to assess changes in utilization of these options in...
2.
Basic E, Kappel M, Misra A, Sellner L, Ratsch B, Ostwald D
Eur J Health Econ
. 2020 Jul;
21(9):1351-1361.
PMID: 32654072
Background: In Germany, several triplet therapies for treating relapsed or refractory multiple myeloma (rrMM) patients have recently been approved. While most of them are administered intravenously, ixazomib-based combination is the...
3.
Mevius A, Brandes A, Hardtstock F, Wilke T, Ratsch B, Orzechowski H, et al.
Digestion
. 2019 Oct;
102(2):216-226.
PMID: 31639807
Objectives: This study aimed to assess the real-world rates of treatment discontinuation and switching of biologic therapies in patients with inflammatory bowel disease (IBD). Methods: A retrospective claims data analysis...
4.
Brandes A, Groth A, Gottschalk F, Wilke T, Ratsch B, Orzechowski H, et al.
Z Gastroenterol
. 2019 Jul;
57(7):843-851.
PMID: 31288280
Objectives: This study aimed to describe biologic treatment of German inflammatory bowel disease (IBD) patients, including biologics' dosage, health care resource use, and treatment-associated cost. Methods: In this retrospective claims...
5.
Georgiadou E, Fanter L, Brandes A, Ratsch B, Friedel H, Dignass A
Z Gastroenterol
. 2019 Mar;
57(5):574-583.
PMID: 30873578
Introduction: Perianal fistulas (PF) are presumably a frequent extraintestinal manifestation of Crohn's disease (CD), causing significant functional impairment. This study aims to gain representative data on the prevalence, characteristics, and...
6.
Wilke T, Mueller S, Bauer S, Pitura S, Probst L, Ratsch B, et al.
Patient Prefer Adherence
. 2018 Dec;
12:2387-2396.
PMID: 30519004
Background And Objectives: This study describes preferences of German relapsed refractory multiple myeloma (RRMM) patients with novel proteasome inhibitor-based combination treatments. Methods: Patients with a minimum age of 18 years...
7.
Pink M, Ratsch B, Mardahl M, Durek P, Polansky J, Karl M, et al.
J Immunol
. 2016 Sep;
197(8):3406-3414.
PMID: 27591321
E- and P-selectin ligands (E- and P-ligs) guide effector memory T cells into skin and inflamed regions, mediate the inflammatory recruitment of leukocytes, and contribute to the localization of hematopoietic...
8.
Pink M, Ratsch B, Mardahl M, Schroter M, Engelbert D, Triebus J, et al.
Mol Immunol
. 2014 Jun;
62(1):1-9.
PMID: 24915132
Fucosyltransferase VII encoded by the gene Fut7 is essential in CD4(+) T cells for the generation of E- and P-selectin ligands (E- and P-lig) which facilitate recruitment of lymphocytes into...
9.
Al Baqlani S, Tien Sy B, Ratsch B, Al Naamani K, Al Awaidy S, Busaidy S, et al.
PLoS One
. 2014 May;
9(5):e97759.
PMID: 24835494
Background: Hepatitis B virus (HBV) infection is a major global health burden with distinct geographic public health significance. Oman is a country with intermediate HBV carrier prevalence; however, little is...
10.
Heidrich B, Yurdaydin C, Kabacam G, Ratsch B, Zachou K, Bremer B, et al.
Hepatology
. 2014 Mar;
60(1):87-97.
PMID: 24585488
Unlabelled: Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24...